Burning Rock Dx

Join Our Webinar on ctDNA and Deep Sequencing ?? April 17, 2025 | ? 8:00 AM (PDT), 11:00 AM (EDT) We’re hosting a webinar focused on the latest advancements and challenges in ctDNA sequencing and deep sequencing technologies. These innovations are transforming precision oncology by enabling non-invasive cancer diagnosis and monitoring through liquid biopsies. We’ll explore how ultra-deep sequencing and deep learning are enhancing the accuracy of detecting rare mutations, crucial for early detection and treatment monitoring. Join us to: 1. Understand ctDNA’s role in treatment selection, MRD monitoring, and early cancer detection. 2. Discover how deep learning improves variant detection accuracy. 3. Learn about cutting-edge innovations in ultra-deep sequencing for low-tumor-burden samples. Don’t miss this opportunity to stay ahead in precision oncology. Register now and gain unlimited on-demand access after the live event: https://lnkd.in/gA9YDAuh #Webinar #PrecisionOncology #BurningRockDx #ctDNA #NGS #CancerResearch?#EarlyDetection

We’re heading to the 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe. From 8th to10th, April, come see us at booth #16, where our team will be ready to discuss the latest in precision medicine and diagnostic innovations. Join xinru mao, our Head of Pharma Services and Global IVD Business, for a presentation on April 9 at 2:20 PM: ???????? ???????????? ???????????? ???? ?????????????? ????????????????????: ?????????? ???????????????????? ???????????? ?????????????????? ????????????????????????. ?? Explaining the unique value of liquid biopsy in patient selection and therapeutic monitoring ?? Showcasing clinical applications of Burning Rock's CanCatch? for MRD-guided treatment adjustments ?? Sharing case studies of ctDNA monitoring in evaluating therapeutic response and enabling personalised treatment strategies We look forward to connecting with you at the summit. See you in London! #PrecisionOncology #BurningRockDx #ClinicalBiomarkers #CDx #LiquidBiopsy #ctDNA

Regular screening can prevent colorectal cancer by detecting and removing precancerous polyps before they turn into cancer. Screening also finds this cancer early when treatment is most effective. If you’re 45 or older, talk to your doctor about getting screened. It’s crucial even if you have no symptoms or family history. Encourage loved ones over 45* to prioritize screening. Explore our Early Cancer Detection Services: https://lnkd.in/giWJqgtK. #ColorectalCancer #BurningRockDx #LiquidBiopsy #PrecisionMedicine #NGS #EarlyDetection

Colorectal cancer (CRC) is a prevalent global health cancer. However, advancements in precision medicine are making a difference. OncoScreen Plus, a CE-Marked 518-gene panel, detects clinically significant biomarkers for CRC, including BRAF, KRAS, NRAS, HRAS, PIK3CA, and MMR genes, to guide personalized treatment decisions. This March, during Colorectal Cancer Awareness Month, let's highlight how genomic testing is improving CRC care. Every test brings us closer to better outcomes.? Check it out here: https://lnkd.in/g7me6_ki #ColorectalCancer #ColorectalCancerAwarenessMonth #BurningRockDx?#CancerTesting #Oncology??

At a recent webinar hosted by Burning Rock, Dr. Yurong Qu, Translational Scientist at Burning Rock, shared her insights on the role of NGS in DDR inhibitor development: “NGS allows us to detect a wide range of mutations, including SNV and CNV, which is essential for identifying biomarkers and optimizing clinical trials. Among the many testing methods, NGS testing has a strong technical advantage.” #BurningRockDx #NGS #PrecisionOncology #GeneticTesting #DDRinhibitor

New Publication from Burning Rock: Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC A groundbreaking study published in The Journal for Immunotherapy of Cancer (IF=10.3) introduces the interaction score for additional chemotherapy (ISAC), a novel approach to stratifying first-line immunotherapy for patients with low PD-L1 expression in non-squamous NSCLC. The study demonstrated that for patients with low ISAC scores, the combination of immunotherapy and chemotherapy significantly outperformed immunotherapy alone. In contrast, for those with high ISAC scores, there was no significant difference in efficacy between the combination therapy and immunotherapy alone. The results of PFS and OS were consistent in the Training set and Validation set, underscoring the reliability of the ISAC. ISAC is a testament to the power of integrating genomics and clinical insights to improve patient outcomes. We look forward to further refining these tools and expanding their application in oncology. Read more about this study and its implications for NSCLC treatment: https://lnkd.in/eV2EKngg #BurningRockDx #NSCLC #immunotherapy #Oncology #PrecisionOncology

On International Women’s Day, Burning Rock celebrates the achievements of women around the world. We recognize their invaluable contributions across all fields. Today, we stand together to support and empower women everywhere, working towards a more inclusive and equal future. ? #IWD2025 #IWD #BurningRockDx #InternationalWomensDay #Leadership #Equity #WomenInLeadership?

BMC Medicine?highlights the critical role of precision diagnostics in advancing cancer care. The study, titled?"Dynamic methylation-based analysis of minimal residual disease in surgical lung cancer patients", explores the potential of DNA methylation-based assays for detecting minimal residual disease (MRD) and postoperative monitoring in lung cancer patients. Key Findings from the Study: 1???Tumor-Informed Methylation Approach: The study introduced a tumor-informed methylation-based MRD (timMRD) approach, which demonstrated superior accuracy in recurrence risk assessment compared to tumor-na?ve methods. 2???Correlation with Tumor Burden: Baseline timMRD-scores were positively correlated with tumor burden, invasiveness, and the presence of somatic mutations. 3???Prognostic Value: Patients with higher timMRD-scores post-surgery had significantly shorter disease-free survival, as validated in both the MEDAL cohort (n=195) and an independent DYNAMIC cohort (n=36). 4???Early Detection: The timMRD approach outperformed traditional ctDNA mutation analysis in identifying relapsed patients, particularly in early-stage (Stage I) and baseline ctDNA-negative cases. It also achieved a remarkable?97.2% negative predictive value?120 days prior to relapse. Role of Burning Rock Dx’s Panel: In this study,?Burning Rock Dx's cutting-edge NGS (Next-Generation Sequencing) panel?played a pivotal role in enabling ultra-deep targeted sequencing and bisulfite sequencing. This technology was instrumental in analyzing matched tumor, tumor-adjacent tissues, and longitudinal blood samples, providing the high-resolution data needed to validate the timMRD approach. Why This Matters: This research underscores the transformative potential of methylation-based MRD detection in postoperative cancer surveillance. By leveraging innovative diagnostic tools like Burning Rock’s NGS panel, we can improve early detection, personalize treatment strategies, and ultimately enhance patient outcomes. https://lnkd.in/gh3bRJck #PrecisionOncology #CancerResearch #MRD #DNAMethylation #LungCancer #BurningRockDx #InnovationInHealthcare #NGS #BMCMedicine